介绍：FMC63抗体是一种针对人CD19的鼠单克隆抗体。CD19是目前CAR-T细胞治疗领域中应用最广泛的靶点，大量研究表明，CD19是治疗B细胞急性淋巴细胞白血病（B-ALL）、慢性淋巴细胞白血病（CLL）和B细胞淋巴瘤等肿瘤有效且安全的靶点。而FMC63抗体的出现，使得CAR-T细胞治疗更加精准、安全。

名称：Anti-CD19 (FMC63) CAR的特异性抗体蛋白

别名：FMC63，B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, Anti-FMC63

链接：https://www.antibodysystem.com/index/search?wd=FMC63

其他产品：

Anti-FMC63 scFv Monoclonal Antibody (SAA1996) (RAD10801)

Anti-Human CD19 scFv Antibody (FMC63) (RHD10803)

Anti-FMC63 scFv Monoclonal Antibody (SAA2162) (RAD10803)

Anti-Human CD19 Antibody (FMC63) (FHD10840)

形式：Liquid

纯度：>95%-98%(SDS-PAGE & RP-HPLC)

Accession：P15391

优势：多种属多标签，高稳定性，高生物活性，高纯度

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

AntibodySystem：

AntibodySystem是由法国ProteoGenix专家团队创立的科研试剂品牌，产品管线覆盖各种病毒研究蛋白/抗体质控品、Invivo功能性抗体，流式抗休、抗药药物靶点蛋白以及其他活性蛋白、PEG抗体，磷酸化抗体、抗DNA抗体、小分子抗体、RUO ELISA试剂盒、生物类似物。

佰乐博生物：佰乐博生物代理antibodysystem，ProteoGenix品牌，是亚洲区运营总代理商

产品购买联系方式：027-65279366 /18162686757

邮箱：biolab-reagents@atagenix.com

QQ：2663991332

参考文献：

Solving the mystery of the FMC63-CD19 affinity. PMID: 38155191

CD19 CAR antigen engagement mechanisms and affinity tuning. PMID: 36867678

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. PMID: 31959992

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line. PMID: 33271901

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. PMID: 33021872

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. PMID: 35981465

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. PMID: 31477906

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. PMID: 38066564

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. PMID: 32894185

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. PMID: 36453632

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy. PMID: 37297020

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. PMID: 36875091

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. PMID: 35222427

Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy. PMID: 33432627

Fully human CD19-specific chimeric antigen receptors for T-cell therapy. PMID: 28202953

Stealth transgenes enable CAR-T cells to evade host immune responses. PMID: 38724463

Preparation and characterization of a chimeric CD19 monoclonal antibody. PMID: 1725979

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. PMID: 33023981

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells. PMID: 38659938

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. PMID: 38475814

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. PMID: 18676854

CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. PMID: 38745250

Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. PMID: 9566763

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells. PMID: 37206593

Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. PMID: 35755944

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design. PMID: 31702909

Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. PMID: 33632869

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. PMID: 35117999

Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. PMID: 33843201

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. PMID: 35355931